fbpx

Marcolin Announces Early Renewal of License Agreement with Guess

Longarone (Belluno) — Marcolin Group announced the early renewal of an exclusive license agreement for the design, manufacture and worldwide distribution of GUESS and Marciano sunglasses and eyeglasses.

The license agreement is extended until 2025, consolidating a partnership and a synergy between the two Groups, which has lasted for over 25 years. GUESS is the pillar brand in the diffusion segment for Marcolin Group, offering eyewear collections which fully embody the core values of the brand, characterized by trendy modern silhouettes. The wide range of sun and optical eyewear includes models for men and women, as well as for children and teenagers.

Giovanni Zoppas, Executive Vice Chairman of Marcolin Group said: “GUESS, one of the most iconic and distinctive lifestyle brands in the fashion industry, and Marcolin Group have always shared an attention for the product’s quality with an aim to keep up with times. We would like to thank Paul Marciano and his GUESS team for, once again, renewing their trust in Marcolin Group. We begin a new chapter of a collaboration that has distinguished itself for over 25 years of the two companies’ history. The license agreement renewal with GUESS reaffirms our solidity and represents another important step in the long-term development and growth plan of Marcolin Group.”

Paul Marciano, Co-Founder of GUESS?, Inc. said: “Throughout the past 25+ years, Marcolin Group has always respected GUESS’ core values and honored the brand’s importance on product quality and trends. Time and time again, they have proven to be a great partner to GUESS and Marciano sunglasses and eyeglasses. We look forward to future success and growth within the eyewear category as we continue to collaborate globally.”

Source: Marcolin

 

Featured Posts

Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read more
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read more
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read more
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read more
Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read More
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read More
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read More
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read More
Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read more
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read more
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read more
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read more
Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read more
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read more
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read more
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read more